Mukul Agarwal
Corporate Officer/Principal chez FORTY SEVEN, INC.
Profil
Mukul Agarwal is currently the Vice President of Corporate Development at Forty Seven, Inc. Prior to this, he worked as the Senior Director of Corporate Development and Strategy at Anacor Pharmaceuticals LLC.
From 2016 to 2019, he was the Vice President of Business Development at Revance Therapeutics, Inc. Mr. Agarwal holds a Master's in Business Administration from Carnegie Mellon University, a graduate degree from The Ohio State University, and an undergraduate degree from the Indian Institute of Technology New Delhi.
Postes actifs de Mukul Agarwal
| Sociétés | Poste | Début |
|---|---|---|
| FORTY SEVEN, INC. | Corporate Officer/Principal | - |
Anciens postes connus de Mukul Agarwal
| Sociétés | Poste | Fin |
|---|---|---|
| REVANCE THERAPEUTICS, INC. | Corporate Officer/Principal | 01/03/2019 |
| ANACOR PHARMACEUTICALS INC | Corporate Officer/Principal | - |
Formation de Mukul Agarwal
| Carnegie Mellon University | Masters Business Admin |
| The Ohio State University | Graduate Degree |
| Indian Institute of Technology New Delhi | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| REVANCE THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Anacor Pharmaceuticals LLC
 Anacor Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Anacor Pharmaceuticals, Inc. develops medical solutions. The firm operates as a biopharmaceutical company, which focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. The company was founded by Lucy Shapiro, Stephen J. Benkovic, and David P. Perry in 2000 and is headquartered in Palo Alto, CA. | Health Technology |
Forty Seven, Inc.
 Forty Seven, Inc. Pharmaceuticals: MajorHealth Technology Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA. | Health Technology |
